Two-Drug combo aims to shrink vulvar tumors before surgery
NCT ID NCT07679841
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This trial tests whether combining an immune-boosting cream (imiquimod) with a low dose of an immunotherapy drug (nivolumab) can shrink vulvar squamous cell carcinoma tumors before surgery. About 50 women with resectable, early-to-moderate stage vulvar cancer will receive the drugs for six weeks prior to their planned operation. The study looks at safety and how well the tumors respond, with the goal of improving surgical outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and imiquimod
What this could lead to
If successful, this combination could shrink vulvar tumors before surgery, potentially making surgery easier and improving long-term control of the disease.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply broadly. The drugs can cause side effects like skin reactions, flu-like symptoms, or immune-related issues that could delay surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VULVAR SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Saint Etienne
Saint-Priest-en-Jarez, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Centre Léon Bérard
Lyon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Groupe Hospitalier Mutualiste de Grenoble
Grenoble, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact